Clinical focus Target opportunities in immunomodulatory therapies for inflammatory conditions, leveraging Ampio's development-stage profile and existing expertise in inflammatory disease mechanisms to position partnerships or out-licensing deals with mid-to-large pharma seeking inflammation franchises.

Strategic partnerships Capitalize on past activity with H.C. Wainwright & Co. and board-level governance changes to approach firms that value financing and strategic advisory relationships; propose capital-efficient collaboration models such as milestone-based collaborations or co-development to mitigate risk.

Financial readiness Ampio’s revenue under one million and recent activity around at-the-market financing termination signals a need for cash-flow friendly deal structures; target opportunities offering upfront funding, development milestones, and potential optioning of assets to ensure rapid value realization.

Market signals Despite closure in 2024, there is residual interest in inflammatory condition therapies; pursue opportunities with contract research organizations or CROs, manufacturing partners, or platforms that can advance or repurpose Ampio’s assets or technology for related indications.

Leadership and governance Engage with investors or firms familiar with Ampio’s leadership transitions and litigation history to present risk-managed investment theses; emphasize transparent governance, regulatory diligence, and robust risk mitigation to win trust for potential asset acquisitions or licensing.